INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 25, 2017-- NantKwest Inc. (Nasdaq:NK), a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced a
View HTML
Toggle Summary NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease
First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initiated For Pancreatic, Lung, Breast, Colon, Melanoma, Sarcoma, Chordoma, Head And Neck, Non Hodgkin’s Lymphoma, Merkel Cell And Ovarian Cancers. First Whole Genome, Transcriptomic, Proteomic (GPS Cancer) Informed
View HTML
Toggle Summary NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 2, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 th , in New York City at
View HTML
Toggle Summary NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team CULVER CITY, Calif. --(BUSINESS WIRE)--May 18, 2017-- NantKwest Inc.  (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural
View HTML
Toggle Summary NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
Company adds esteemed pediatric, adolescent and young adult oncology expert to leadership team CULVER CITY, Calif. --(BUSINESS WIRE)--May 16, 2017-- NantKwest Inc . (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune
View HTML
Toggle Summary NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--May 15, 2017-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that members of the company's management team will be presenting at the 2017 Bank of America Healthcare Conference on Thursday, May
View HTML
Toggle Summary NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer
The NANT Cancer Vaccine, the First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation Personalized Molecular Informed Therapy with NantHealth's GPS Cancer as the Complementary Diagnostic for All Tumor Types A Cancer
View HTML
Toggle Summary NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA   April 4, 2017 -  NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc . announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc .
View HTML
Toggle Summary NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest to Present at Upcoming Investor Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen & Company’s 37th Annual Healthcare Conference on Wednesday, March 8th , at 9:20am ET
View HTML